Author name: Leonardo Arias

Durante décadas, la agricultura industrial ha operado bajo una premisa de eficiencia geométrica: vastas extensiones de tierra dedicadas a una sola especie vegetal. Sin embargo, la ciencia edafológica y la ecología del suelo han puesto al descubierto el elevado coste ocult …

A finales del Pleistoceno, hace aproximadamente entre 50.000 y 11.000 años, el planeta presenció uno de los colapsos ecológicos más drásticos y misteriosos de la historia reciente de la Tierra. De la noche a la mañana, en términos geológicos, l …

Newly permanent CBER and CDER directors Karim Mikhail and Michael Davis are widely expected to continue the FDA’s efforts toward an adaptive framework for rare disease therapies. If approved by the Senate, will commissioner nominee Heidi Overton stay the course?

Delivering therapeutics directly to tumors, as in the case of Replimune’s recently approved Tudriqev and Amgen’s Imlygic, holds advantages, especially when cancer is caught early, but challenges remain before the method becomes a mainstay in treatment.

As molecule complexity rises, advanced cell line development platforms are giving biopharma companies new tools to overcome expression challenges, improve stability and reach the clinic faster.

About 12 million Americans can’t access telehealth because broadband is unavailable or slow, according to new research. Most live in rural areas, which experts say could benefit heavily from better access to virtual care.

The sale lets Ascension shed insurance risk while Aetna gains a stake in a profitable plan serving high-margin dual-eligible members.

A new five-year biotech plan has been released by the Chinese government, revealing ambitious goals such as achieving five blockbuster medicines on the global markets in that time.

The robot is intended to give physicians more control of the endoscope during a colonoscopy procedure, which can help with detection and removal of lesions.

Electra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ipsoprubart.